Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So I checked the instys that filed looking if any new ones got added since 11/15. Low and behold, SIG reported on 11/15 that all put, call, and about 260,000 shares were exited during the last quarter. Then on the 20th, it went from all exited to all 3 positions being reduced. So, now we are back to over 10 Million shares held by instys.
How often does that happen?
Read one comment behind. Lt is calling the pr fluff even though it's a pr about being reviewed by other professionals in their respective fields.
Peer review is fluff now? Lol
I think we are all aware of the prestigious people who dropped out of college and created their own empire most college grads would dream of.
DD is good ONLY if it's done correctly. Doing a background, worse, college one on someone that has been in the FDA for over 20 years has NO meaning. You might think it does, but most know what's going on. Nothing but a sideshow trying to gain attention.
Now if you were to do some DD on a-273, I'd be all ears.
Well, I'm sure you'll start seeing the name a lot more in the coming years
Oh no, even IF trials run behind schedule for some unknown reason, I will still be here. Missling and EVERYONE below him is top notch in their respective field
Pharma investing is a tricky thing
"So he does have right information but does not share it to protect from shorts? How many times I have heard this excuse being used on boards"
I never said that. What I did say was that he is keeping data not only from shareholders BUT ALSO the shorts and BP that could very well possibly be waiting on more data.
Thanks for trying to understand a simple paragraph though.
He stated multiple times trials start by end of year. Last time I checked there's still a whole December before the year ends.
Never understand the logic in investing in a company where one doesn't believe in the CEO and board to get things done.
If I ever feel like Missling is lying to ME, I'll quietly exit my position. No need to yell it on a board or seem like a sour investor that lost money.
I'd gladly bring up your conversational banter in exactly 365 days from today just to see where we stand then compared to today.
I know, you were around just as long as I.
He's not only hiding information from company shareholders, he's also hiding info from the short cabal as well as the sharks that are circling the company waiting to aggressively takeover the co. Believe it or not, it does happen.
As long a Missling continues to implement his plan for the company, and data remains positive, time is on our, the longs, side.
Now is not the time to grow impatient just when the "iceburg" is about to set sail.
Then again, everyone has their own opinion.
I suspect you didn't think they were transparent 2 years ago when they pr'd a lot more and even was called a pr scam machine. Damned if they do damned if they don't.
Either way, science WILL put the pps in its correct spot eventually no matter if they communicate with impatient shareholders that don't understand what by end of year means.
Whats the chances of A-273 being designated Regenerative Medicine Advanced Therapy Designation (RMAT)?
Interesting that it states the following:
"The request for RMAT designation must be made either concurrently with submission of an Investigational New Drug application (IND) or as an amendment to an existing IND. We will not grant a RMAT designation if an IND is on hold or is placed on hold during the designation review."
then:
"To be clear, we remain committed to ensuring that patients have access to safe and effective regenerative medicine products as efficiently as possible."
I don't care what the pps right now, things are starting to warm up behind the scenes.
Meager? With everyone on different doses and still finding positives within the entire group?
Wait till p2/3 and if results are the same, then its meager.
Still would be better than soc though. Which would still get approved if that happened.
Seems like a perfect phrase to use.
cautiously optimistic:
hopeful about something, but recognizing the problems involved
Remember that the P2 trials were not dose optimized so any efficacy is a plus.
vivek ramaswamy already took that spot.
Isn't that just about 12 months?
ok, maybe 13, but no where near the 3 years as being pushed around by some nefarious people.
In Bill Gates own words:
"There are many ways an Alzheimer’s drug might help prevent or slow down the disease. Most drug trials to date have targeted amyloid and tau, two proteins that cause plaques and tangles in the brain. I hope those approaches succeed, but we need to back scientists with different, less mainstream ideas in case they don’t. A more diverse drug pipeline increases our odds of discovering a breakthrough."
Missling himself said around 300 patients so that point is moot debating.
Revamping the FDA guidelines helps speed up the process of getting access of said drug to patient, as long as it is safe. So again, 2-3 years is a bit far fetched. Especially with 25 patients already in the 2-3 year realm and still providing useful data. So the p2a/b continuing data along with the p2/3 at even 1 year would get the longs here across the finish line.
With Axon, NTRP, BIIB and every other BP failing to provide a better than soc treatment for Alz, it's taking the little pharmas to lead the charge and discover new possibilities only to then get bought out by BP. Now, do you REALLY think BIIB didn't try and buy Anavex on the cheap?
Ill dare to guess that come next friday, insties will have a larger position than 24%
I believe he stated Partnership "WHEN THE TIME COMES".
Anavex, the company, is worth more today with 3rd party research proving it could benefit multiple cns diseases.
pps is just smoke and mirrors trying to incite panic selling.
% of shares held by Instys, if higher than 24%, will also prove shorts are full of fud.
Lol @ #4. Can't make that stuff up. The imagination on some people.
You only lose if you sell. Did you sell today? would you say you made money if we were up $6.
If one can't handle the swings, maybe another stock is where one should invest in.
Investing is a tricky thing.
I'm curious how much shares are tied up with posters on the board.
Don't think so? As much credit as I put in anything that comes from someone that repeatedly says has "no interest" in the stock, sure post a lot of fud here.
Watch how it won't cost billions to do a trial like before. The wheels are starting to roll and this conference was just another tick on the list of accomplishments that need to be completed.
Truely, administering a pill a day seriously can't amount to an unobtainable trial completion, can it?
For the 100th time, financing is good even WITH trials starting per Missling. If you don't believe it or doubt it, then why invest in a ticker that you have no trust in the CEO to execute his job.
That's the funny difference between a pump and dump and a more realistic approach to pps.
How many pump and dumps has Anavex had since the big manipulation to $14 and back down to the $4s?
If one isn't willing to be patient, there are a lot of P&D tickers out there.
So a company MC is something an investor should factor into when investing?
Poor Axon investors that didn't get the constant warning that the company was a scam.
If a co has a promising drug candidate for multiple diseases is also something that should be factored in. Which is when one invests what one can afford to possibly lose since nothing is a guaranteed. However, it's something most on this board understand and patiently waits for the next set of trials to start and adjust their investment when the appropriate time comes.
We shall see in the next 6 months how everything turns out. Until then, most on this board have done their DD and ignore garbage trying to bring up the education of a former 25 year FDA employee. Does one HAVE to go to an Ivy League to be considered smart? That's quite a fortune to take on loan when the end result could be a job where one gets paid $.05 $.10 a post.
I'd love to hear your thoughts on tomorrow's presentation.
Funny how the part in red was left out the first time while explaining his education. Besides, after 25 years in the FDA, does education still matter?
At these manipulated prices? 100% Negative.
With better news ahead, more likely.
Nice one, too bad the federal government didn't catch that phony of a degree of his. What were they thinking hiring people like that to the FDA.
Then again, if Adam can be a bio analyst with his wonderful educational background......
Keep dreaming my friend and one day your dreams will come true too, he who was a pilot in the bush.
Even biogen uses words such as may or what was those other words.....? Quote taken straight from their biogen ms twitter
Remyelination may lead to improvements in neurologic function in people #LivingwithMS #MSParis2017
Perspective in that tweet with a vid in which Gilmore O'Neill said it.
Sounds like he's talking right to Anavex and the promise that a-273 has.
Wish I could link it for you guys.just look at @biogenms on twitter
Wayne State just about to take the stage. 237 just got done presenting
Biogen and Eisai Agree to Work Together on Alzheimer’s Therapy Aducanumab
A true 99.8% failure rate drug
Biogen and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters.
The U.S. and Japanese companies are already collaborating on the development of elenbecestat (E2609) and BAN2401, which also target beta amyloid.
https://alzheimersnewstoday.com/2017/10/26/biogen-and-eisai-will-work-together-to-further-develop-alzheimers-therapy-aducanumab/
Makes for an interesting Nov. 6 opening bell. = )
Veronica Francardo, the Dr. and author of the therapeutics poster, used that very same title some years ago.
“Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism”
Interesting read to see how she thought of sigma-1 back in 2014.
In the last years several studies also reported anti-amnesic and neuroprotective effects of Sig-1R ligands in animal models of AD (Maurice and Su, 2009). Clinical trials in patients with AD are now ongoing (further informations can be found at www.anavex.com), and the aim for the future is to accelerate the steps from preclinical to clinical trials also on PD patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281425/
Actually, it could very well be there this time next year. Eternity avoided.